Standard Biotools is trading 5.37% lower at $0.60, with no company-specific announcement identified for October 23. - Its latest listed release was the October 5 agreement to sell its Microfluidics business. - Healthcare-sector weakness is relevant context: Quest Diagnostics disclosed unauthorized access to a lab-services system and possible access to patient records. - This is sector-level context, not evidence the Quest incident directly caused Standard Biotools’ decline.